ストックスクリーナーアプリを入手
25.80
1.34%
-0.391
前日終値:
$26.19
開ける：
$26.74
24時間の取引高:
744.11K
Relative Volume:
0.64
時価総額：
$1.87B
収益：
$193.35M
当期純損益:
$-177.58M
株価収益率:
-10.53
EPS:
-2.45
ネットキャッシュフロー:
$-172.43M
1週間 パフォーマンス:
+0.96%
1か月 パフォーマンス:
+18.53%
6か月 パフォーマンス:
+38.33%
1年 パフォーマンス:
+5.51%
1日の値動き範囲:
$25.77
$26.89
1週間の範囲:
$23.57
$26.89
52週間の値動き範囲:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
SDGR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
25.81 | 1.87B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
214.49 | 36.24B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
52.11 | 9.99B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
42.54 | 7.43B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
83.03 | 7.20B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.32 | 6.36B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-02 | 開始されました | Leerink Partners | Outperform |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | 再開されました | Piper Sandler | Overweight |
| 2022-12-19 | 開始されました | Goldman | Neutral |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-10-13 | 開始されました | Berenberg | Buy |
| 2021-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | 開始されました | Craig Hallum | Buy |
| 2020-11-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-10-12 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-02 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-02 | 開始されました | Jefferies | Hold |
| 2020-03-02 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Schrodinger Inc (SDGR) 最新ニュース
3 Momentum Stocks That Could Soar Post-Market Volatility - Investing.com
3 Momentum Stocks That Could Soar Post-Market Volatility - MarketBeat
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - 01net
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger (NASDAQ:SDGR) shareholders are up 29% this past week, but still in the red over the last five years - simplywall.st
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? - MSN
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued - Yahoo Finance
Schrodinger price target raised to $32 from $30 at KeyBanc - TipRanks
Schrodinger’s Karen Akinsanya sells $419,570 in stock By Investing.com - Investing.com South Africa
Schrodinger’s Karen Akinsanya sells $419,570 in stock - Investing.com
Schrodinger issues statement on FDA phasing out animal testing requirement - TipRanks
FDA recent move marks paradigm shift in drug development, boosting Schrödinger (SDGR) and other biotech stocks - Investorsobserver
Schrodinger (SDGR) Backs FDA's Initiative to Cut Animal Testing in Drug Development | SDGR Stock News - GuruFocus
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal T - GuruFocus
Schrödinger backs FDA’s move away from animal testing By Investing.com - Investing.com South Africa
Schrodinger to Launch Predictive Toxicology Tool in H2 - marketscreener.com
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs - 01net
Schrödinger backs FDA’s move away from animal testing - Investing.com Australia
Schrödinger'S Statement Regarding FDA Plan To Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs - MarketScreener
Vanguard Group Inc. Lowers Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) - Seeking Alpha
Schrödinger (SDGR) Reveals Promising Preclinical Data for Cancer Inhibitors - GuruFocus
Schrodinger Settles Lawsuit Over Director Compensations; Shares Up - MarketScreener
Schrödinger (SDGR) Faces Cash Burn Challenges Amid Growth - GuruFocus
Schrodinger settles director pay lawsuit, to reform governance By Investing.com - Investing.com South Africa
Schrodinger settles director pay lawsuit, to reform governance - Investing.com
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements - Benzinga
Schrodinger Stock Hits 52-Week Low at $16.64 Amid Market Challenges - Investing.com
Schrödinger, Inc. (NASDAQ:SDGR) Shares Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Top 5 AI & Digital Biotech Companies (April 2025) - Securities.io
Swiss National Bank Has $2.41 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Schrödinger Finally Embraces AI – Is It a Buy? - Nanalyze
Schrödinger to Present Preclinical Data at AACR Annual Meeting - 01net
Schrödinger to Present at Four Investor Conferences in September - Business Wire
(SDGR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Schrodinger Inc (SDGR) Trading Down 1.72% on Mar 21 - GuruFocus.com
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus By Investing.com - Investing.com South Africa
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus - Investing.com India
(SDGR) Proactive Strategies - Stock Traders Daily
Proficio Capital Partners LLC Purchases Shares of 11,285 Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger adds Bridget van Kralingen to board By Investing.com - Investing.com Australia
Schrodinger at Leerink Global: Strategic Growth and Challenges - Investing.com India
Schrodinger appoints Bridget van Kralingen to board By Investing.com - Investing.com Canada
Schrödinger Appoints Bridget van Kralingen To Board - citybiz
Schrodinger appoints Bridget van Kralingen to board - Investing.com
Schrödinger adds Bridget van Kralingen to board - Investing.com India
Schrodinger Inc (SDGR) 財務データ
収益
当期純利益
現金流量
EPS
Schrodinger Inc (SDGR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
0.70%
0.41%
大文字化:
|
ボリューム (24 時間):